GENE ONLINE|News &
Opinion
Blog

2022-05-11| Asia-PacificM&A

Bora Pharmaceuticals Expands with Eden Biologics’ CDMO Purchase

by Fujie Tham
Share To

Taiwanese Bora Pharmaceuticals recently announced the establishment of Bora Biologics CDMO platform, and ready to invest $100M to acquire Eden Biologics’ CDMO assets, securing its leading position in Taiwan’s contract development and manufacturing organization (CDMO) market. 

Acquisition of Eden’s CDMO facilities at Hsinchu Biomedical Science Park in Taiwan will jumpstart Bora Group’s first presence in the macromolecules, cell and gene therapy markets, a dramatic and significant shift from the company’s previous focus on small molecule drug manufacturing. With this buy, Bora will obtain cell lines development technologies for protein drugs manufacturing, upstream and downstream processes, quality control setups, etc., components crucial in widening its service offering.

Related article: Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells

 

Bora’s 5-Year CDMO Growth Project

 

The company has been diversifying rapidly over the past few years, with manufacturing sites set up on multiple continents. Just last month, Bora extended its Oral Solid Dose capabilities to a purpose-built site in Ontario, Canada, with funding for more than $10M over the next 2 years.

Seeking to reduce production costs, drug designers often arrange their manufacturing with CDMOs, for a reduction in costs connected to manufacturing, packaging, and testing, to improve gross margin while maintaining high product and manufacturing quality. In December 2021, the CDMO also acquired a GSK plant in Canada, symbolizing its first manufacturing footprint in Northern America.

Bora’s large share in the manufacturing field certainly will attract drug makers and therapeutics startups to do business with it while bolstering Taiwan’s position in the global pharmaceutical supply chain.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
JPM 2024: Taiwan’s Pharma Giant Bora Pharmaceuticals Climbing US Pharmaceutical Summit
2024-01-10
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
EVENT
Scroll to Top